Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309341610> ?p ?o ?g. }
- W4309341610 endingPage "100629" @default.
- W4309341610 startingPage "100629" @default.
- W4309341610 abstract "Evaluation of health-related quality of life (HR-QoL) among cancer patients has gained an increasing importance and is now a key determinant of anticancer treatments' value. HR-QoL has been assessed in trials testing cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in breast cancer (BC), using various questionnaires at different timepoints. HR-QoL reports from BC patients treated with CDK4/6i in the real-world setting are also available.We systematically reviewed the literature, searching for full-length articles, and selected conference abstracts reporting data on HR-QoL in BC patients at any stage and of any molecular subtype treated with abemaciclib, palbociclib or ribociclib.A total of 533 full-length articles and 143 abstracts were retrieved. After screening for eligibility, 38 records were included (31 clinical trials; 7 real-world reports). Assessment methods were heterogeneous across studies in terms of questionnaires, evaluation timepoints and endpoints. Overall, adding CDK4/6i to endocrine therapy did not worsen patients' HR-QoL, with a positive trend towards pain improvement. Gastrointestinal scores (diarrhea, nausea and appetite loss) statistically favored the control arm among metastatic BC patients receiving abemaciclib, whereas they were superimposable in the early setting. The combination of palbociclib and endocrine therapy showed similar HR-QoL outcomes compared with endocrine therapy alone, but determined better scores compared with chemotherapy. HR-QoL was specifically assessed in premenopausal patients treated with ribociclib, showing similar scores compared with postmenopausal patients.Despite methodological heterogeneity does not allow a proper comparison, HR-QoL was generally maintained with CDK4/6i. However, differences between abemaciclib, palbociclib and ribociclib exist and mainly rely on the distinct safety profiles of the compounds. These differences should be acknowledged and taken into account in the clinical practice." @default.
- W4309341610 created "2022-11-26" @default.
- W4309341610 creator A5001957610 @default.
- W4309341610 creator A5009976972 @default.
- W4309341610 creator A5025684262 @default.
- W4309341610 creator A5033355348 @default.
- W4309341610 creator A5034676299 @default.
- W4309341610 creator A5038676900 @default.
- W4309341610 creator A5039051729 @default.
- W4309341610 creator A5051163510 @default.
- W4309341610 creator A5054386184 @default.
- W4309341610 creator A5061264992 @default.
- W4309341610 creator A5074479074 @default.
- W4309341610 date "2022-12-01" @default.
- W4309341610 modified "2023-10-14" @default.
- W4309341610 title "Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review" @default.
- W4309341610 cites W2134119471 @default.
- W4309341610 cites W2279074305 @default.
- W4309341610 cites W2313479654 @default.
- W4309341610 cites W2318131634 @default.
- W4309341610 cites W2344792835 @default.
- W4309341610 cites W2552099557 @default.
- W4309341610 cites W2560635244 @default.
- W4309341610 cites W2572704941 @default.
- W4309341610 cites W2605489431 @default.
- W4309341610 cites W2620993107 @default.
- W4309341610 cites W2763875663 @default.
- W4309341610 cites W2787301578 @default.
- W4309341610 cites W2791840917 @default.
- W4309341610 cites W2798042703 @default.
- W4309341610 cites W2805669343 @default.
- W4309341610 cites W2805729741 @default.
- W4309341610 cites W2883737490 @default.
- W4309341610 cites W2887856562 @default.
- W4309341610 cites W2896846857 @default.
- W4309341610 cites W2901884329 @default.
- W4309341610 cites W2908699784 @default.
- W4309341610 cites W2920384425 @default.
- W4309341610 cites W2945156880 @default.
- W4309341610 cites W2948069739 @default.
- W4309341610 cites W2970684805 @default.
- W4309341610 cites W2976566015 @default.
- W4309341610 cites W2978195283 @default.
- W4309341610 cites W2981679955 @default.
- W4309341610 cites W2982150569 @default.
- W4309341610 cites W2994903788 @default.
- W4309341610 cites W3005879958 @default.
- W4309341610 cites W3010575887 @default.
- W4309341610 cites W3013244914 @default.
- W4309341610 cites W3020482066 @default.
- W4309341610 cites W3026119116 @default.
- W4309341610 cites W3034640356 @default.
- W4309341610 cites W3045121257 @default.
- W4309341610 cites W3087561595 @default.
- W4309341610 cites W3087819517 @default.
- W4309341610 cites W3088973135 @default.
- W4309341610 cites W3097362850 @default.
- W4309341610 cites W3115380088 @default.
- W4309341610 cites W3116128628 @default.
- W4309341610 cites W3118615836 @default.
- W4309341610 cites W3120214487 @default.
- W4309341610 cites W3138543041 @default.
- W4309341610 cites W3145237130 @default.
- W4309341610 cites W3148345241 @default.
- W4309341610 cites W3157512122 @default.
- W4309341610 cites W3167855488 @default.
- W4309341610 cites W3169955705 @default.
- W4309341610 cites W3174844543 @default.
- W4309341610 cites W3195183235 @default.
- W4309341610 cites W3195746645 @default.
- W4309341610 cites W3196278183 @default.
- W4309341610 cites W3202325290 @default.
- W4309341610 cites W3204829131 @default.
- W4309341610 cites W3205928766 @default.
- W4309341610 cites W3214231894 @default.
- W4309341610 cites W4200066800 @default.
- W4309341610 cites W4200389952 @default.
- W4309341610 cites W4200476614 @default.
- W4309341610 cites W4205572275 @default.
- W4309341610 cites W4206349107 @default.
- W4309341610 cites W4206666777 @default.
- W4309341610 cites W4214529556 @default.
- W4309341610 cites W4220812022 @default.
- W4309341610 cites W4220833656 @default.
- W4309341610 cites W4220931687 @default.
- W4309341610 cites W4221085715 @default.
- W4309341610 cites W4376849475 @default.
- W4309341610 doi "https://doi.org/10.1016/j.esmoop.2022.100629" @default.
- W4309341610 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36399953" @default.
- W4309341610 hasPublicationYear "2022" @default.
- W4309341610 type Work @default.
- W4309341610 citedByCount "6" @default.
- W4309341610 countsByYear W43093416102023 @default.
- W4309341610 crossrefType "journal-article" @default.
- W4309341610 hasAuthorship W4309341610A5001957610 @default.
- W4309341610 hasAuthorship W4309341610A5009976972 @default.
- W4309341610 hasAuthorship W4309341610A5025684262 @default.
- W4309341610 hasAuthorship W4309341610A5033355348 @default.